Rangering i aksjer
#23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Aksjekurs
$1.81
Sist synkronisert: 2026-08-21
Handel Annovis Bio, Inc. (ANVS)
Pris ANVS pris med markedsverdi på B
Markedsverdi av Annovis Bio, Inc.(ANVS)
Markedsverdi: $77.00M
Per August 2026 har Annovis Bio, Inc. en markedsverdi på $77.00M. Dette gjør Annovis Bio, Inc. til det 23205th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Annovis Bio, Inc. fra 2020 til 2026
ANVS sammenlignet med topp 5 mest populære stocks
| Pris på ANVS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.211T
|
+6,767,871.37%
|
|
|
|
|
$4.547T
|
+5,904,729.87%
|
|
|
|
|
$4.162T
|
+5,405,680.85%
|
|
|
|
|
$3.593T
|
+4,665,834.28%
|
|
|
|
|
$2.793T
|
+3,626,962.00%
|
